SARS-CoV-2 Serum Viral Load and Prognostic Markers Proposal for COVID-19 Pneumonia in Low-Dose Radiation Therapy Treated Patients

Pique, Berta; Peña, Karla; Riu, Francesc; Acosta, J.; Torres-Royo, L.; Malave, Bárbara; Araguas, P.; Benavides, Rocío; Febrer, Gabriel de; Camps, Jordi; Joven, Jorge; Arenas, Meritxell; Parada, David

doi:10.3390/jcm12030798

Cited by 2 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may reflect that severe COVID-19 is typically caused by lower respiratory tract infection, which may not be detected by nasal and/or nasopharyngeal swabbing, and in the case of VL at diagnosis, may also reflect that severe disease may take days or weeks to fully manifest. This result contrasts with previous studies which have documented associations between VL at diagnosis or during the second week of infection and severe disease. Importantly, however, prior studies were conducted primarily in hospitalized populations, and our study is unique in its capture of individuals with COVID-19 symptoms in a primarily outpatient context.…”

Section: Discussioncontrasting

confidence: 99%

“…SARS-CoV-2 Viral Load in the Nasopharynx Among Unvaccinated Individuals VL at diagnosis [46][47][48][49][50] or during the second week of infection 40 and severe disease. Importantly, however, prior studies were conducted primarily in hospitalized populations, and our study is unique in its capture of individuals with COVID-19 symptoms in a primarily outpatient context.…”

Section: Jama Network Open | Infectious Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals

Fisher,

Kee,

Liu

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceSARS-CoV-2 viral load (VL) in the nasopharynx is difficult to quantify and standardize across settings, but it may inform transmission potential and disease severity.ObjectiveTo characterize VL at COVID-19 diagnosis among previously uninfected and unvaccinated individuals by evaluating the association of demographic and clinical characteristics, viral variant, and trial with VL, as well as the ability of VL to predict severe disease.Design, Setting, and ParticipantsThis secondary cross-protocol analysis used individual-level data from placebo recipients from 4 harmonized, phase 3 COVID-19 vaccine efficacy trials sponsored by Moderna, AstraZeneca, Janssen, and Novavax. Participants were SARS-CoV-2 negative at baseline and acquired COVID-19 during the blinded phase of the trials. The setting included the US, Brazil, South Africa, Colombia, Argentina, Peru, Chile, and Mexico; start dates were July 27, 2020, to December 27, 2020; data cutoff dates were March 26, 2021, to July 30, 2021. Statistical analysis was performed from November 2022 to June 2023.Main Outcomes and MeasuresLinear regression was used to assess the association of demographic and clinical characteristics, viral variant, and trial with polymerase chain reaction–measured log10 VL in nasal and/or nasopharyngeal swabs taken at the time of COVID-19 diagnosis.ResultsAmong 1667 participants studied (886 [53.1%] male; 995 [59.7%] enrolled in the US; mean [SD] age, 46.7 [14.7] years; 204 [12.2%] aged 65 years or older; 196 [11.8%] American Indian or Alaska Native, 150 [9%] Black or African American, 1112 [66.7%] White; 762 [45.7%] Hispanic or Latino), median (IQR) log10 VL at diagnosis was 6.18 (4.66-7.12) log10 copies/mL. Participant characteristics and viral variant explained only 5.9% of the variability in VL. The independent factor with the highest observed differences was trial: Janssen participants had 0.54 log10 copies/mL lower mean VL vs Moderna participants (95% CI, 0.20 to 0.87 log10 copies/mL lower). In the Janssen study, which captured the largest number of COVID-19 events and variants and used the most intensive post-COVID surveillance, neither VL at diagnosis nor averaged over days 1 to 28 post diagnosis was associated with COVID-19 severity.Conclusions and RelevanceIn this study of placebo recipients from 4 randomized phase 3 trials, high variability was observed in SARS-CoV-2 VL at the time of COVID-19 diagnosis, and only a fraction was explained by individual participant characteristics or viral variant. These results suggest challenges for future studies of interventions seeking to influence VL and elevates the importance of standardized methods for specimen collection and viral load quantitation.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Jama Network Open | Infectious Diseasesmentioning

confidence: 99%

SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals

Fisher,

Kee,

Liu

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

show abstract

Current issues of post-covid syndrome consequences

Krasnoselskyi,

Starenkyi,

Artamonova

et al. 2023

УРОЖ

View full text Add to dashboard Cite

Background. The World Health Organization (WHO) has confirmed the outbreak of covid infection and defined it as a global pandemic. Recently, complications have been increasingly reported in patients who have had COVID-19. At the same time, clinical symptoms of the long-term course of this disease overlap, differing from acute manifestations of the infection, and may persist in recovered patients for several weeks, months or years, adding a number of other problems. Therefore, the importance of a thorough study of the post-COVID-19 syndrome as a modern phenomenon has increased. And this syndrome requires proper research to improve the efficiency of its prevention and treatment. Purpose. To evaluate the current state of the problem of post-COVID-19 syndrome, in particular in cancer patients. Materials and methods. A literature review was performed based on the array of digital publications found in the world databases PubMed, Scopus and Web of Science Core Collection for 2020–2023. The sources were systematized in separate groups, i.e., issues related to post-Covid, in particular, the mechanisms and pathogenesis of its development; treatment features, including cancer patients; long-term consequences in recovered patients, etc. Results and discussion. The terminology on the subject of the study has been analyzed: post-COVID, post-COVID syndrome, PASC, long-COVID, acute COVID, chronic COVID, etc. The views regarding the pathogenesis of post-COVID syndrome and its main symptoms were systematized. It is determined that in the field of oncology, research is conducted in certain fields and the risk of progression and occurrence of cancer in the post-COVID period is evaluated; the efficiency of the process of cancer care organization in the post-COVID period and the level of complications and mortality of cancer patients who have suffered from COVID-19. The pandemic has also led to multiple changes in the field of radiological diagnosis of the consequences of cancer patients with COVID. Evaluating the impact of the pandemic on the outcomes and adaptation of radiotherapy and chemotherapy, it was determined that delays in the provision of timely care and changes in treatment regimens will affect long-term survival of cancer patients. Conclusion. Assessing the current state of the problem of post-COVID syndrome, most researchers believe that cancer progression during delay in cancer care will negatively affect the long-term survival of cancer patients, and coincidence of cancer-related symptoms and symptoms of long-term COVID is another major challenge for oncologists in the future.

show abstract

SARS-CoV-2 Serum Viral Load and Prognostic Markers Proposal for COVID-19 Pneumonia in Low-Dose Radiation Therapy Treated Patients

Cited by 2 publications

References 35 publications

SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals

SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals

Current issues of post-covid syndrome consequences

Contact Info

Product

Resources

About